Combination of Stereotactic Body Radiation Therapy and STAT3 Protein Inhibitor TTI-101 for Borderline Resectable and Locally Advanced Pancreatic Cancer
Study Background
Pancreatic cancer patients have a five‑year survival rate of less than 10%. While conventional stereotactic body radiation therapy (SBRT) improves local control and transient immune responses, it has not translated into long‑term survival benefits.
Mechanism and Objectives
The STAT3 protein inhibitor TTI‑101 is expected to amplify inflammatory signaling while attenuating fibrosis and immune suppression, thereby synergizing with SBRT to enhance its benefits and reduce toxicity. This study aims to improve 2‑year progression‑free survival (PFS) by leveraging the post‑chemotherapy treatment window.
Clinical Design
The trial is a Phase 1, ACTIVE_NOT_RECRUITING study that commenced on January 16 2024. Eligible participants are patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma. The primary endpoints are safety and 2‑year progression‑free survival.
Expected Benefits and Risks
If the combination of the STAT3 inhibitor and SBRT proves successful, it could add a novel maintenance therapy option to existing chemotherapy, radiation, and surgery regimens. Conversely, increased toxicity or a lack of synergistic effect could lead to trial termination.
Combining a STAT3 inhibitor with radiation therapy offers a differentiated immune‑activating effect for early‑stage biopharma pipelines, enhancing their investment appeal. Such innovative therapies strengthen a company's clinical development capabilities and create new opportunities for job seekers entering the field.
Source: ClinicalTrials.gov (api_ct)